Lipitoids, which self-assemble with DNA and RNA, can serve as cellular delivery systems for antiviral therapies that could prevent COVID-19 and other coronavirus infections. (Illustration courtesy of R.N. Zuckermann)
Cellular delivery system developed at Berkeley Lab’s Molecular Foundry could be missing link in battle against SARS-CoV-2
A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.
Last year, Stanley Qi, an assistant professor in the departments of bioengineering, and chemical and systems biology at Stanford University and his team had begun working on a technique called PAC-MAN – or Prophylactic Antiviral CRISPR in human cells – that uses the gene-editing tool CRISPR to fight influenza.
But that all changed in January, when news of the COVID-19 pandemic emerged. Qi and his team were suddenly confronted with a mysterious new virus for which no one had a clear solution. “So we thought, ‘Why don’t we try using our PAC-MAN technology to fight it?’” said Qi.
Since late March, Qi and his team have been collaborating with a group led by Michael Connolly, a principal scientific engineering associate in the Biological Nanostructures Facility at Berkeley Lab’s Molecular Foundry, to develop a system that delivers PAC-MAN into the cells of a patient.
Like all CRISPR systems, PAC-MAN is composed of an enzyme – in this case, the virus-killing enzyme Cas13 – and a strand of guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus’s genome. By scrambling the virus’s genetic code, PAC-MAN could neutralize the coronavirus and stop it from replicating inside cells.
It’s all in the delivery
Qi said that the key challenge to translating PAC-MAN from a molecular tool into an anti-COVID-19 therapy is finding an effective way to deliver it into lung cells. When SARS-CoV-2, the coronavirus that causes COVID-19, invades the lungs, the air sacs in an infected person can become inflamed and fill with fluid, hijacking a patient’s ability to breathe.
“But my lab doesn’t work on delivery methods,” he said. So on March 14, they published a preprint of their paper, and even tweeted, in the hopes of catching the eye of a potential collaborator with expertise in cellular delivery techniques.
Soon after, they learned of Connolly’s work on synthetic molecules called lipitoids at the Molecular Foundry.
Lipitoids are a type of synthetic peptide mimic known as a “peptoid” first discovered 20 years ago by Connolly’s mentor Ron Zuckermann. In the decades since, Connolly and Zuckermann have worked to develop peptoid delivery molecules such as lipitoids. And in collaboration with Molecular Foundry users, they have demonstrated lipitoids’ effectiveness in the delivery of DNA and RNA to a wide variety of cell lines.
Today, researchers studying lipitoids for potential therapeutic applications have shown that these materials are nontoxic to the body and can deliver nucleotides by encapsulating them in tiny nanoparticles just one billionth of a meter wide – the size of a virus.
Now Qi hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundry’s growing body of lipitoid delivery systems.
In late April, the Stanford researchers tested a type of lipitoid – Lipitoid 1 – that self-assembles with DNA and RNA into PAC-MAN carriers in a sample of human epithelial lung cells.
According to Qi, the lipitoids performed very well. When packaged with coronavirus-targeting PAC-MAN, the system reduced the amount of synthetic SARS-CoV-2 in solution by more than 90%. “Berkeley Lab’s Molecular Foundry has provided us with a molecular treasure that transformed our research,” he said.
The team next plans to test the PAC-MAN/lipitoid system in an animal model against a live SARS-CoV-2 virus. They will be joined by collaborators at New York University and Karolinska Institute in Stockholm, Sweden.
If successful, they hope to continue working with Connolly and his team to further develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses, and to explore scaling up their experiments for preclinical tests.
“An effective lipitoid delivery, coupled with CRISPR targeting, could enable a very powerful strategy for fighting viral disease not only against COVID-19 but possibly against newly viral strains with pandemic potential,” said Connolly.
“Everyone has been working around the clock trying to come up with new solutions,” added Qi, whose preprint paper was recently peer-reviewed and published in the journal Cell. “It’s very rewarding to combine expertise and test new ideas across institutions in these difficult times.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Two doses of Oxford University Covid-19 vaccine produces stronger immune response than oneon June 23, 2020 at 6:00 am
In trials on pigs researchers found the vaccine being developed by scientists at Oxford appears to work better in a two-part 'prime' and 'boost' dosage - the same way the MMR jab is given.
- Breakthrough: Indian scientists find COVID-19 gene in wastewater, hailed by global communityon June 22, 2020 at 7:40 am
Scientists in India have for the first time detected genetic material of the SARS-CoV-2 virus in wastewater, a breakthrough that paves the way for using wastewater-based epidemiology (WBE) for ...
- Indian scientists find Covid gene in wastewater — a breakthrough in tracking virus outbreakon June 22, 2020 at 1:39 am
The study conducted on Ahmedabad's wastewater paves the way for using wastewater-based epidemiology for real-time surveillance of Covid-19 in India.
- In possible breakthrough, Israeli lab claims successful vaccine trial on rodentson June 20, 2020 at 9:01 pm
Defense Ministry-run Institute for Biological Research says it has been able to protect hamsters from COVID-19, hopes to have finished product for humans within a year ...
- Duo of antiviral drugs strongly inhibits SARS-CoV-2 in the labon June 19, 2020 at 12:52 am
A combination of two antiviral drugs can strongly inhibit the new coronavirus in cell culture experiments, potentially paving the way for a treatment.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Older adults may be left out of some COVID-19 trialson June 23, 2020 at 10:30 am
Picture the day — in six months, a year and a half or in 2023 — when university researchers or a pharmaceutical company announces a breakthrough against the virus that causes COVID-19.
- COVID-19 Has Leveled the Playing Field for People With Disabilitieson June 23, 2020 at 8:17 am
The pandemic has pushed society into a newly accessible world, creating opportunities for people previously restricted by illness or disability.
- Gilead to study inhalable form of remdesivir — a possible COVID-19 breakthroughon June 22, 2020 at 9:38 pm
An inhalable version of the antiviral drug remdesivir has been developed and will be tested this summer on COVID-19 patients at their own homes, a potential breakthrough for a drug that has until now ...
- Gilead to study inhalable form of remdisivir - a possible COVID-19 breakthroughon June 22, 2020 at 8:57 pm
The pharmaceutical company that makes the antiviral drug remdesivir, which has shown promise as a treatment for COVID-19, will begin trials for an inhalable version of the medication this summer as ...
- Coronavirus Racial Disparity Revealed; COVID-19 Treatment Breakthroughon June 18, 2020 at 8:54 pm
Mortality rate of COVID-19 for minorities is as much as 10 times higher than in white Americans; A new UK study shows that giving the generic steroid drug Dexamethasone to COVID-19 patients admitted ...